Topic: nonalcoholic steatohepatitis (NASH)
Galmed unveiled top-line results from a yearlong phase 2b study of its NASH treatment, showing reductions in liver fat without worsening fibrosis.
Metacrine raised $65 million to launch phase 1 testing of its FXR agonist in NASH and gastrointestinal diseases later this month.
Nimbus reined in $65 million in funding for its virtual drug discovery and expand into new targets in immunology, oncology and metabolic diseases.
Using an old Roche drug, Madrigal Pharmaceuticals has seen its stock soar 130% on its latest fatty liver disease trials data.
The financing will see Inventiva through a period in which it will drop data from a phase 2b NASH trial and a two-year carcinogenicity study.
The buyout gives Promethera control of a TNF receptor 1 inhibitor it hopes will amplify the effects of cell therapy HepaStem.
The Big Pharma is paying $30 million upfront to pick up the rights to the program and take it into the clinic.
Conatus Pharma’s lead drug emricasan missed the mark in its first midstage clinical test, driving down its stock.
The Terns deal is a poster child of "Lilly China Innovation and Partnerships," a new model in place of Lilly's Shanghai R&D center shuttered last September.
Shares in the company rocket after biotech says tipelukast cut triglyceride levels significantly in patients with nonalcoholic fatty liver disease.